The emergence of COVID-19 associated mucormycosis: a review of cases from 18 countries

ECMM and ISHAM collaborators

Research output: Contribution to journalReview articlepeer-review

210 Citations (Scopus)


Reports of COVID-19-associated mucormycosis have been increasing in frequency since early 2021, particularly among patients with uncontrolled diabetes. Patients with diabetes and hyperglycaemia often have an inflammatory state that could be potentiated by the activation of antiviral immunity to SARS-CoV2, which might favour secondary infections. In this Review, we analysed 80 published and unpublished cases of COVID-19-associated mucormycosis. Uncontrolled diabetes, as well as systemic corticosteroid treatment, were present in most patients with COVID-19-associated mucormycosis, and rhino-orbital cerebral mucormycosis was the most frequent disease. Mortality was high at 49%, which was particularly due to patients with pulmonary or disseminated mucormycosis or cerebral involvement. Furthermore, a substantial proportion of patients who survived had life-changing morbidities (eg, loss of vision in 46% of survivors). Our Review indicates that COVID-19-associated mucormycosis is associated with high morbidity and mortality. Diagnosis of pulmonary mucormycosis is particularly challenging, and might be frequently missed in India.

Original languageEnglish
Pages (from-to)e543-e552
JournalThe Lancet Microbe
Issue number7
Publication statusPublished - Jul 2022


Dive into the research topics of 'The emergence of COVID-19 associated mucormycosis: a review of cases from 18 countries'. Together they form a unique fingerprint.

Cite this